Gold on Your Gift List
Frank Holmes (November 19th, 2009) Writes:
Britain, Buffalo, Christmas, Frank Holmes;, Frank Talk, Indian Government, Investing Lessons, USD, world gold council
Frank Holmes (November 19th, 2009) Writes:
Contrarian Profits (November 13th, 2009) Writes:
If You Thought the Housing Meltdown Was Bad… Doug Hornig, Senior Editor, (Casey Research):
…wait until you see what’s in the cards for commercial real estate.
That’s right, the next train wreck will be in commercial real estate. Couldn’t be worse than last year’s residential market crash? That remains to be seen. But it’s coming soon, probably as early as the second quarter of next year, and there’s nothing that can prevent it. The government will intervene, trying desperately to delay the day of reckoning, and may even succeed. For a while. But make no mistake about it, that train is going off the tracks no matter what.
Every part of the sector – from multifamily apartment buildings to retail shopping centers, suburban office buildings, industrial facilities, and hotels – has accumulated a huge amount of defaulted or nonperforming paper. It’s an impossible, swaying structure that cannot long stand.
Just ask Andy Miller.
Andy
...
Zacks Market Commentaries (November 13th, 2009) Writes:
For Immediate Release
Chicago, IL – November 13, 2009 – Zacks Equity Research highlights Expedia Inc. (EXPE) as the Bull of the Day and Triumph Group, Inc. (TGI) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Target (TGT), TJ Maxx/Marshall’s (TJX) and Abercrombie & Fitch (ANF).
Full analysis of all these stocks is available at http://at.zacks.com/?id=5506
Here is a synopsis of all five stocks:
Expedia Inc. (EXPE) is one of the leading online travel companies in the world. The company reported strong results in the last quarter, beating the Zacks Consensus Estimate. Promotional activity continues to have a positive impact on the conversion rate, and spending is expected to strengthen in the next few quarters.
We are also positive about international initiatives, which we think will be the key to future growth.
...
Dirk Van Dijk (November 12th, 2009) Writes:
Dirk Van Dijk (November 12th, 2009) Writes:
David Blair (November 10th, 2009) Writes:

The stock market is nothing if not a place of pure deception. Just when you think you have the market figured out it changes course leaving you scratching your head in frustration. Or even worse, just when the market seems to be making logical sense it makes no sense whatsoever, which seems to be the case most of the time anyway.
LOGICAL DECEPTION
Think about the following: all you hear in the news media is how the consumer is not spending any money; how the Christmas season will be dismal; how continued unemployment will stifle any improvement in consumer sentiment, etc. etc. yet have you taken a look at the retail sector in the last few months? The RTH (Retail Holders Trust) broke out yesterday to a high it has not seen since the
...
Dirk Van Dijk (November 6th, 2009) Writes:
In general though, the pace of job losses has been slowing, especially if you step back and look at the big picture. Over the last three months, the economy has been dropping an average of
...
Zacks Market Commentaries (November 6th, 2009) Writes:
For Immediate Release
Chicago, IL – November 6, 2009 – Zacks Equity Research highlights Acorda Therapeutics (ACOR) as the Bull of the Day and Canon (CAJ) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Big Lots (BIG), Wal-Mart (WMT) and Nordstrom (JWN).
Full analysis of all these stocks is available at http://at.zacks.com/?id=5506
Here is a synopsis of all five stocks:
Acorda Therapeutics (ACOR) is one of the more interesting biotechnology companies under our coverage. The company's key pipeline drug, Fampridine-SR, is currently under U.S. FDA review, with a decision expected in late January 2010.
Outside the U.S., Acorda has partnered with Biogen Idec under very favorable terms. Fampridine-SR has blockbuster potential worldwide in our view. Plus, the company is extremely well-capitalized with over $290 million in cash, and management has commercial experience
...
Dirk Van Dijk (November 5th, 2009) Writes:
Dr. Stock Pick (November 4th, 2009) Writes:
Dr Stock Pick HOT News & Alerts!
_______________________________________
FREE Daily Stock Alerts From DrStockPick.com
_______________________________________
Wednesday November 4, 2009
DrStockPick.com Stock Report!
**************************************************************
Power3 Medical Products, Inc. (OTCBB: PWRM), a leader in neurodegenerative disease and cancer biomarkers and diagnostic tests, announces further international recognition of validity as the company’s President and CSO, Dr. Ira Goldknopf, will deliver an invited Keynote address and chair a session on “Biomarkers and Diagnostics in Personalized Medicine (Track 6-4),” at the BIT Life Sciences 2nd International Congress and Expo of Molecular Diagnostics in Beijing, China, November 19-21, 2009. The Theme of the meeting is “New Leadership of
...